Current scenario of cancer clinical trials in India

Ruckmani A, Geetha Lakshmi G and Madhavi Eerike
Chettinad Hospital & Research Institute, India

It is well known that, cancer is a leading cause of death worldwide. According to WHO approximately 14 million new cases and 8.2 million cancer related deaths were reported in 2012. In India, as per the data in 2014, 8 lakhs new cases and 5.5 lakhs deaths occur every year. Such high morbidity and mortality of cancers do not only affect the individual but the family and the society at large in terms of lack of health, expenditure on treatment & economic productivity. The treatment of cancer is expensive and not affordable to all. There is an urgent need to make anticancer drugs available & affordable to the common people. Considering the cost & toxicity of most of the anticancer drugs, new drug trials become a necessity. In this context this paper will give a detailed analysis of registered cancer trials both conducted & ongoing in India. In India clinical trials are conducted after registering with Clinical trial registry, India (CTRI). As per this registry, approximately more than 5900 clinical trials were registered from 2007. Out of this more than 700 are cancer trials. These trials have been analyzed in terms of cancer type, the phase of trial or BA/BE, the candidate drug whether new, existing or new formulation/route, adjuvant therapy and discuss their outcome and future directions.

Biography

Ruckmani A is currently the Head of the department of pharmacology at Chettinad Hospital & Research Institute, Chennai and previously in various Government medical colleges in Tamil Nadu from 1998. She serves as Member Secretary for the Institutional and Chair person for the outside ethics committees and member in various academic committees. She is the coordinator for the course; M Sc Clinical Research & Experimental Medicine. She has conducted clinical trials and published more than 40 research papers in indexed journals. She serves as a Guide for PhD & MD, M Sc Postgraduates.

ruckmani.nirmal@gmail.com

Notes: